Value Of Multi-Indication Immunotherapies For The Treatment Of Autoimmune Diseases In The United States

A conversation with Long Nguyen

A single therapy targeting multiple diseases sounds like a win-win for patients and drug makers, but the reality is far more complicated. Research into multi-indication immunotherapies in the U.S. reveals a calculated approach to market entry. According to Long Nguyen, whose team investigated this trend, manufacturers often launch with the most prevalent and highest-value indication first to establish a favorable price point. While this is a logical business strategy, the research uncovers a concerning trend: the value provided by each subsequent indication tends to decrease as the price increases. This raises important questions about equitable access and sustainable pricing models.

To understand the surprising data gaps and the next steps for this critical research, continue reading our conversation with Long Nguyen.